Phase II Study of RR110 in Patients With Active Crohn's Disease
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics profile of
1 and 4 mg/kg/day RR110 administrated orally for 8 weeks in patients with active Crohn's
disease.